The Renin-Angiotensin System in Essential Hypertension
Information source: St George's, University of London
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Enalapril 20 mg bd (Drug); Candesartan 8 mg bd (Drug)
Phase: N/A
Status: Terminated
Sponsored by: St George's, University of London Official(s) and/or principal investigator(s): Timothy WR Doulton, BSc MRCP, Principal Investigator, Affiliation: SGUL
Summary
Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure
lowering agents, the exact mechanisms by which these agents lower BP are still not fully
understood. This study aims to compare the blood pressure and hormonal responses (plasma
renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in
individuals with mild essential hypertension.
Clinical Details
Official title: The Renin-Angiotensin System in Essential Hypertension
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: Change in BPChange in PRA and aldosterone
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Essential Hypertension
- SBP 140-159 mmHg
- DBP 90-99 mmHg
Exclusion Criteria:
- Intolerance of or allergy to ACE Inhibitors or ARBS
- Pregnant or Breastfeeding
- Pre-menopausal women
- Uncontrolled cardiac or renal failure
- Diabetes mellitus
Locations and Contacts
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL, London SW17 0RE, United Kingdom
Additional Information
Starting date: April 2004
Last updated: June 5, 2015
|